1st-qtr sales at Ipsen leap 19%

27 April 2017

French drugmaker Ipsen (Euronext: IPSEY) today announced consolidated group sales for the first quarter of 2017 of 438.0 million ($476.5 million), a rise of 19.1% on the like year-earlier period, with the news sending its shares up 2.8% at 102.70 euros late morning, having hit 104.00 euros at the start of trading.

The sales increase was driven by Specialty Care growth of 25.4% to 366.5 million euros, including growth of 86.3%from North America.

Commenting on the performance, chief executive David Meek said: “In the first quarter, Specialty Care continued to drive remarkable organic top-line growth for Ipsen, led by the outstanding performance of Somatuline, both in the United States and Europe, as well as a strong acceleration for Dysport. We continue to face headwinds in certain emerging markets for our Consumer Healthcare business.”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK